Key Points
- Insider sale: Cerus insider Chrystal Jensen sold 30,000 shares at an average price of $2.98, generating $89,400. After the transaction, Jensen retained 936,657 shares.
- Business performance: Cerus reported quarterly revenue of $63.3 million, slightly above estimates, and EPS of $(0.01), in line with consensus. The company continues to operate with negative profitability metrics.
- Investor outlook: Institutional investors own 78.37% of Cerus shares, while analyst opinions remain mixed; the stock has an overall “Hold” rating and a consensus price target of $4.00.
Cerus Corporation (NASDAQ:CERS - Get Free Report) insider Chrystal Jensen sold 30,000 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $2.98, for a total value of $89,400.00. Following the transaction, the insider owned 936,657 shares in the company, valued at $2,791,237.86. This trade represents a 3.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Chrystal Jensen also recently made the following trade(s):
- On Tuesday, June 30th, Chrystal Jensen sold 24,329 shares of Cerus stock. The shares were sold at an average price of $2.94, for a total value of $71,527.26.
Cerus Stock Performance
NASDAQ:CERS opened at $2.97 on Tuesday. The company has a market capitalization of $598.51 million, a price-to-earnings ratio of -99.00 and a beta of 1.81. The business has a 50 day moving average of $2.81 and a 200 day moving average of $2.43. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.83 and a quick ratio of 1.07. Cerus Corporation has a 1-year low of $1.15 and a 1-year high of $3.47.
Cerus (NASDAQ:CERS - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biotechnology company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01). Cerus had a negative net margin of 3.06% and a negative return on equity of 10.19%. The firm had revenue of $63.30 million for the quarter, compared to the consensus estimate of $62.90 million. On average, sell-side analysts predict that Cerus Corporation will post -0.04 earnings per share for the current fiscal year.
Institutional Trading of Cerus
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CERS. Globeflex Capital L P bought a new position in Cerus in the 4th quarter worth $1,076,000. Levin Capital Strategies L.P. purchased a new position in shares of Cerus during the first quarter valued at about $461,000. UBS Group AG raised its stake in Cerus by 227.1% in the fourth quarter. UBS Group AG now owns 1,142,502 shares of the biotechnology company's stock worth $2,354,000 after buying an additional 793,244 shares in the last quarter. Round Rock Advisors LLC purchased a new stake in Cerus in the fourth quarter worth about $545,000. Finally, Primecap Management Co. CA bought a new stake in Cerus during the 2nd quarter valued at approximately $2,283,000. Hedge funds and other institutional investors own 78.37% of the company's stock.
Analyst Ratings Changes
CERS has been the subject of several recent research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Cerus in a research note on Thursday, June 18th. Zacks Research upgraded Cerus from a "strong sell" rating to a "hold" rating in a report on Thursday, April 30th. BTIG Research raised Cerus from a "neutral" rating to a "buy" rating and set a $4.00 price target on the stock in a research note on Friday, May 1st. Finally, Wall Street Zen downgraded Cerus from a "buy" rating to a "hold" rating in a research report on Saturday. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $4.00.
Check Out Our Latest Research Report on CERS
About Cerus
(
Get Free Report)
Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.
The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
